SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Cardiovascular Pharmacology and Therapeutics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Dorian, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dorian, P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Antiarrhythmic Action ofß-Blockers: Potential Mechanisms

Paul Dorian, MD

Division of Cardiology, St. Michael’s Hospital, University of Toronto, Ontario, Canada

Sympathetic nervous system overactivity has been linked to ventricular tachyarrhythmias and sudden death. It has been hypothesized that the extent and nature of the arrhythmogenic effect of sympathetic stimulation depends on the underlying myocardial substrate, the mechanism of the arrhythmia, and the integrated effects of sympathetic stimulation in the particular individual circumstance. Multiple direct and indirect mechanisms of adrenergic action on the heart may benefit from the known antiarrhythmic actions of ß-blocker therapy and other interventions that decrease sympathetic tone. The antiarrhythmic mechanism of ß-blockade (and possibly {alpha}-blockade) will depend on the specific mechanism of the individual arrhythmia and will differ for those arrhythmias caused by tachycardia and ischemia, those caused by reentry and promoted by decreased conduction velocity and shortened refractoriness, and those caused by early or delayed afterdepolarizations, usually in the context of prolonged action potential duration. Antagonism of cardiac adrenergic activity by ß-blockade in particular is the best-established drug therapy to prevent ventricular arrhythmias.

Key Words: ß-blockers • ventricular arrhythmia • adrenergic

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 10, No. 4 suppl, S15-S22 (2005)
DOI: 10.1177/10742484050100i403


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J Intensive Care MedHome page
M. W. Dunser and W. R. Hasibeder
Sympathetic Overstimulation During Critical Illness: Adverse Effects of Adrenergic Stress
J Intensive Care Med, September 1, 2009; 24(5): 293 - 316.
[Abstract] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
B. N. Singh
{beta}-Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Compounds: An Overview
Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S3 - S14.
[Abstract] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
S. H. Hohnloser
Ventricular Arrhythmias: Antiadrenergic Therapy for the Patient with Coronary Artery Disease
Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S23 - S31.
[Abstract] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
J. A. Reiffel
Drug and Drug-Device Therapy in Heart Failure Patients in the Post-COMET and SCD-HeFT Era
Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S45 - S58.
[Abstract] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
P. R. Kowey
A Review of Carvedilol Arrhythmia Data in Clinical Trials
Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S59 - S68.
[Abstract] [PDF]



Advertisement